<DOC>
	<DOCNO>NCT02278250</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple ascend dos single-agent VX-803 administer twice-weekly ( BIW ) subject advanced solid tumor . This investigation three part study examine VX-803 alone combination carboplatin , gemcitabine , cisplatin determine safety maximum tolerate dose .</brief_summary>
	<brief_title>An Open-Label Study Safety , Tolerability , Pharmacokinetic/Pharmacodynamic Profile VX-803 Single Agent Combination With Cytotoxic Chemotherapy Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Part A : Subjects one histologically cytologically confirm malignant advance solid tumor , standard therapy available may convey clinical benefit Part B : Subjects one histologically cytologically confirm malignant advance solid tumor , standard therapy available may convey clinical benefit and/or subject must progress least 1 prior chemotherapy regimen metastatic setting , carboplatin ( Part B1 ) , gemcitabine ( Part B2 ) , cisplatin ( Part B3 ) would consider standard care . Part C : Subjects advance ( locally advance incurable metastatic ) histologically cytologically confirm highgrade serous ovarian cancer ( high nuclear Grades 2 3 ) . Subjects either platinumrefractory ( disease progression initial platinum therapy ) platinumresistant ( disease progression &lt; 6 month completion platinum therapy ) disease . Measurable disease accord RECIST criterion ( Version 1.1 ) WHO performance status 0 1 Life expectancy ≥12 week Hematological biochemical index within acceptable range Screening . Radiotherapy , unless brief course palliative therapy , endocrine therapy , immunotherapy , chemotherapy 4 week ( 6 week nitrosoureas MitomycinC , 4 week investigational medicinal product ) 4 drug halflives first dose study drug , whichever great Part B : More 6 cycle prior therapy carboplatin Parts B1 , B3 , C : During prior platinum therapy , requirement dose reduction discontinuation carboplatin cisplatin toxicity lack tolerability Ongoing toxic manifestation previous treatment . Exceptions alopecia certain Grade 1 toxicity , opinion investigator exclude subject . Any known history Grade 4 thrombocytopenia prior chemotherapy regimen Spinal cord compression brain metastasis unless asymptomatic , treated , stable , require steroid least 4 week first dose study drug Female subject already pregnant lactating , plan become pregnant within 6 month last dose study drug exclude . Female subject childbearing potential must adhere contraception guideline . Female subject consider nonchildbearing potential undergone surgical hysterectomy bilateral oophorectomy amenorrheic 2 year screen serum folliclestimulating hormone ( FSH ) level within laboratory 's reference range postmenopausal female . Male subject partner childbearing potential must agree adhere contraception guideline . Men pregnant lactate partner partner plan become pregnant study within 6 month last dose study drug exclude . Major surgery ≤4 week first dose study drug incomplete recovery prior major surgical procedure Serious comorbid medical condition , include clinicallysignificant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>